Immunoregulatory mechanisms in multiple myeloma

Hematology/Oncology Clinics of North America

Volumn 11, Issue 1, 1997, Pages 51-69

  Munshi, N C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B LYMPHOCYTE; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOREGULATION; MACROPHAGE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030889390     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70415-9     Document Type: Article

References (92)

1. A.K. Abbas L.L. Perry B.A. Bach Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants J Immunol 124 1980 1160
2. J. Andersson J. Buxbaum R. Citronbaum IgM-producing tumors in the BALB-c mouse: A model for B-cell maturation J Exp Med 140 1974 742
3. M. Andersson G. Holm A.K. Lefvert Anti-idiotypic B-cell lines from a patient with monoclonal gammopathy of undetermined significance Scand J Immunol 30 1989 489
4. B. Baltz P. Gray B. Wagner Reconstitution of high LAK activity after autologous bone marrow transplantation is a poor prognostic factor for patients with multiple myeloma Blood 80 1992 122a
5. S. Bergenbrant A. Osterborg G. Holm Anti-idiotypic antibodies in patients with monoclonal gammopathies: Relation to the tumour load Br J Haematol 78 1991 66
6. S. Bergenbrant Q. Yi E. Osby Anti-idiotypic B lymphocytes in patients with monoclonal gammopathies Scand J Immunol 40 1994 216
7. S. Bergenbrant Q. Yi A. Osterborg Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients Br J Haematol 92 1996 840
8. A. Bianchi L. Dodd J. Kornbluth Selective deficiency in the ability of LAK cells from patients with multiple myeloma to lyse myeloma tumor cells Blood 76 1990 201a
9. A. Bianchi P. Gray J. Kornbluth High levels of LAK activity induced from the bone marrow of multiple myeloma patients Blood 78 1991 115a
10. A. Bianchi L. Montacchini P. Barral CD3-induced T-cell activation in the bone marrow of myeloma patients: Major role of CD4+ cells Br J Haematol 90 1995 625
11. H.S. Birgens F. Espersen J.B. Hertz Antibody response to pneumococcal vaccination in patients with myelomatosis Scand J Haematol 30 1983 324
12. S. Broder R. Humphrey M. Durm Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. Role of suppressor cells N Engl J Med 293 1975 887
13. S. Broder L. Muul M. Megson Abnormalities of immunoregulatory cells in immunodeficiency disease and cancer Prog Clin Biol Res 58 1981 93
14. A. Carter I. Silvian I. Tatarsky Impaired immunoglobulin synthesis in multiple myeloma: A B-cell dysfunction Am J Hematol 22 1986 143
15. H.M. Chapel M. Lee The use of intravenous immune globulin in multiple myeloma Clin Exp Immunol 97 1994 21
16. Y. Chen N. Bhoopalam B.S. Yakulis Changes in lymphocyte surface immunoglobulins in myeloma and the effect of an RNA-containing plasma factor Ann Intern Med 83 1975 625
17. G. Famularo A. D'Ambrosia F. Quintieri Natural killer cell frequency and function in patients with monoclonal gammopathies J Clin Lab Immunol 37 1992 99
18. W.H. Fridman C. Sautes J.L. Teillaud Immunoglobulin-binding factors Immunol Lett 20 1989 249
19. W.H. Fridman J.L. Teillaud C. Bouchard Soluble Fc gamma receptors [see comments] J Leukoc Biol 54 1993 504
20. M.J. Frikke S.H. Bridges R.G. Lynch Myeloma-specific antibodies: Studies of their properties and their relationship to tumor immunity J Immunol 118 1977 2206
21. R. Garcia-Sanz M. Gonzalez A. Orfao Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications Br J Haematol 93 1996 81
22. M. Gonzalez J.F. San Miguel A. Gascon Increased expression of natural-killer-associated and activation antigens in multiple myeloma Am J Hematol 39 1992 84
23. R.M. Hargreaves J.R. Lea H. Griffiths Immunological factors and risk of infection in plateau phase myeloma J Clin Pathol 48 1995 260
24. J. Harris R. Alexanian E. Hersh Immune function in multiple myeloma: Impaired responsiveness to keyhole limpet hemocyanin Can Med Assoc J 104 1971 389
25. F. Herrmann A. Lochner B. Jauer Lymphocyte subsets in the peripheral blood of patients with multiple myeloma and benign monoclonal gammopathy Klinische Wochenschrift 61 1983 819
26. D.M. Hilbert M.Y. Shen U.R. Rapp T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors Proc Natl Acad Sci USA 92 1995 649
27. R.G. Hoover J. Kornbluth Immunoregulation of murine and human myeloma Hematol Oncol Clin North Am 6 1992 407
28. R.G. Hoover R.G. Lynch Isotype-specific suppression of IgA: Suppression of IgA responses in BALB/c mice by T alpha cells J Immunol 130 1983 521
29. R.G. Hoover B.K. Dieckgraefe R.G. Lynch T cells with Fc receptors for IgA: Induction of T alpha cells in vivo and in vitro by purified IgA J Immunol 127 1981 1560
30. R.G. Hoover S. Hickman H.M. Gebel Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma J Clin Invest 67 1981 308
31. R.G. Hoover C. Lary R. Page Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16 J Clin Invest 95 1995 241
32. R.A. Ioannidis D.E. Joshua P.T. Warburton Multiple myeloma: Evidence that light chains play an immunoregulatory role in B-cell regulation Hematol Pathol 3 1989 169
33. T. Ishiyama K. Watanabe K. Fukuchi The increase of CD5LOW+NK cells in patients with multiple myeloma and plasmacytoma Anticancer Res 14 1994 725
34. J. Kornbluth Potential role of CD28-B7 interactions in the growth of myeloma plasma cells Curr Top Microbiol Immunol 194 1995 43
35. J. Kornbluth T. Snead R. Page Effective treatment of established human myeloma tumors in SCID mice with human natural killer cells and interleukins (IL2 and IL4) Blood 82 1993 263a
36. L.W. Kwak D.D. Taub P.L. Duffey Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor Lancet 345 1995 1016
37. H.M. Lazarus M. Lederman A. Lubin Pneumococcal vaccination: The response of patients with multiple myeloma Am J Med 69 1980 419
38. H. Ludwig E. Fritz [Lymphocyte subpopulations in multiple myeloma. Shift in the helper/suppressor cell relation] Acta Medica Austriaca 9 1982 215
39. R.G. Lynch R.J. Graff S. Sirisinha Myeloma proteins as tumor-specific transplantation antigens Proc Natl Acad Sci USA 69 1972 1540
40. R.G. Lynch A. Mathur T.J. Waldschmidt Immunoglobulin (Fc) receptors on murine T- and B-lymphocytes: Investigations using tumor models Mol Immunol 25 1988 1151
41. R.G. Lynch M. Sandor T.J. Waldschmidt Lymphocyte Fc receptors: Expression, regulation and function Mol Immunol 27 1990 1167
42. M.R. MacKenzie T. Paglieroni V. Caggiano CD5 positive immunoregulatory B cells in spleen populations from multiple myeloma patients Am J Hematol 37 1991 163
43. M. Massaia C. Attisano S. Peola Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells Blood 82 1993 1787
44. M. Massaia A. Bianchi C. Attisano Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex [see comments] Blood 78 1991 1770
45. M. Massaia P. Borrione C. Attisano Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients Blood 85 1995 3679
46. C. Mathiot J.L. Teillaud M. Elmalek Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma J Clin Immunol 13 1993 41
47. Mathur A. van Ness B.G. R.G. Lynch In vivo and in vitro regulation of IgE production in murine hybridomas J Immunol 145 1990 3610
48. H. Mellstedt G. Holm D. Pettersson T cells in monoclonal gammopathies Scand J Haematol 29 1982 57
49. B.R. Meyers S.Z. Hirschman J.A. Axelrod Current patterns of infection in multiple myeloma Am J Med 52 1972 87
50. A. Miguel-Garcia E. Matutes F. Tarin Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy J Clin Pathol 48 1995 835
51. K.H. Mills J.C. Cawley Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: Relationship to treatment and clinical stage Br J Haematol 53 1983 271
52. N.C. Munshi L.M. Ding A. Srivastava Soluble CD-16 from AAV mediated CD-16 gene transfer to human cell lines is lytic to multiple myeloma cell lines Blood 82 1993 264a
53. M. Nelson R.D. Brown J. Gibson Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma Br J Haematol 81 1992 223
54. H. Nielsen H.J. Nielsen N. Tvede Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors Apmis 99 1991 340
55. H.M. Ogmundsdottir Natural killer cell activity in patients with multiple myeloma Cancer Detect Prev 12 1988 133
56. A. Osterborg B. Nilsson M. Bjorkholm Natural killer cell activity in monoclonal gammopathies: Relation to disease activity Eur J Haematol 45 1990 153
57. A. Osterborg Q. Yi S. Bergenbrant Idiotype-specific T cells in multiple myeloma stage I: An evaluation by four different functional tests Br J Haematol 89 1995 110
58. T. Paglieroni V. Caggiano M. MacKenzie Abnormalities in immune regulation precede the development of multiple myeloma Am J Hematol 40 1992 51
59. T. Paglieroni M.R. MacKenzie V. Caggiano Abnormalities in immunoregulatory CD5+ B cells precede the diagnosis of multiple myeloma Ann NY Acad Sci 651 1992 486
60. L.M. Pilarski E.J. Andrews M.J. Mant Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function J Clin Immunol 6 1986 491
61. L.M. Pilarski E.J. Andrews H.M. Serra Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstro¨m's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance Am J Hematol 30 1989 53
62. L.M. Pilarski M.J. Mant B.A. Ruether Pre-B cells in peripheral blood of multiple myeloma patients Blood 66 1985 416
63. L.M. Pilarski M.J. Mant B.A. Ruether Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients J Clin Invest 74 1984 1301
64. L.M. Pilarski M.J. Mant B.A. Ruether Abnormal clonogenic potential of T cells from multiple myeloma patients Blood 66 1985 1266
65. L.M. Pilarski M. Piotrowska-Krezolak D.J. Gibney Specificity repertoire of lymphocytes from multiple myeloma patients. I. High frequency of B cells specific for idiotypic and F(ab′)2-region determinants on immunoglobulin J Clin Immunol 5 1985 275
66. L.M. Pilarski B.A. Ruether M.J. Mant Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels J Clin Invest 75 1985 2024
67. L. Pricop H. Rabinowich P.A. Morel Characterization of the Fc mu receptor on human natural killer cells. Interaction with its physiologic ligand, human normal IgM, specificity of binding, and functional effects J Immunol 151 1993 3018
68. S. Quesada R. Leo H. Deicher Functional and biochemical characteristics of a soluble B lymphocyte proliferation-inhibiting activity produced by bone marrow cells from multiple myeloma patients Cell Immunol 162 1995 275
69. G. Reibnegger H. Wachter M. Krainer Hyperreactive cellular immunity in multiple myeloma [letter; comment] Blood 79 1992 2174
70. J.W. Rohrer R.G. Lynch Antigen-specific regulation of myeloma cell differentiation in vivo by carrier-specific T cell factors and macrophages J Immunol 121 1978 1066
71. J.W. Rohrer B. Odermatt R.G. Lynch Idiotype-specific suppression of MOPC-315 IgA secretion in vivo: Reversible blockade of secretory myeloma cells by soluble mediators J Immunol 121 1978 1799
72. J.W. Rohrer B. Odermatt R.G. Lynch Immunoregulation of murine myeloma: Isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo J Immunol 122 1979 2011
73. S.E. Salmon Immunoglobulin synthesis and tumor kinetics of multiple myeloma Semin Hematol 10 1973 135
74. G.C. Saunders M. Wilder Repetitive maturation cycles in a cultured mouse myeloma J Cell Biol 51 1971 344
75. I. Schedel Application of immunoglobulin preparation in multiple myeloma Morell A. Clinical Use of Intravenous Immunoglobulins 1986 Academic Press London 123
76. I. Schedel P. Beck D. Peest Peripheral blood lymphocyte subpopulations in multiple myeloma Adv Exp Med Biol 114 1979 833
77. I. Schedel D. Peest K. Stunkel Idiotype-bearing peripheral blood lymphocytes in human multiple myeloma and Waldenstro¨m's macroglobulinaemia Scand J Immunol 11 1980 437
78. H.M. Serra M.J. Mant B.A. Ruether Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients J Clin Immunol 8 1988 259
79. C. Shimazaki J. Atzpodien D. Wisniewski Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells Acta Haematol 80 1988 203
80. G.T. Stevenson J. Thompson Idiotypes and anti-idiotypes in myeloma Hematol Oncol 6 1988 103
81. C. Teillaud J. Galon M.T. Zilber Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses Blood 82 1993 3081
82. A. Tienhaara T.T. Pelliniemi Peripheral blood B lymphocytes in multiple myeloma Acta Haematol 91 1994 57
83. A. Tienhaara T.T. Pelliniemi Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance Clin Lab Haematol 16 1994 213
84. G. Tricot D.H. Vesole S. Jagannath Graft-versus-myeloma effect: Proof of principle Blood 87 1996 1196
85. J.J. Twomey Infections complicating multiple myeloma and chronic lymphocytic leukemia Arch Intern Med 132 1973 562
86. J.J. Twomey A.H. Laughter L. Rice Suppression of lymphocyte responses by monocytes with untreated and treated multiple myeloma Blood 60 1982 316
87. A. Uchida M. Yagita H. Sugiyama Strong natural killer (NK) cell activity in bone marrow of myeloma patients: Accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells Int J Cancer 34 1984 375
88. S. Ullrich S. Zolla-Pazner Immunoregulatory circuits in myeloma Clin Haematol 11 1982 87
89. L.F. Verdonck H.M. Lokhorst A.W. Dekker Graft-versus-myeloma effect in two cases Lancet 347 1996 800
90. A.J. Wearne D.E. Joshua G.A. Young Multiple myeloma: Light chain isotype suppression—a marker of stable disease at presentation Eur J Haematol 38 1987 43
91. A. Winkelstein P.S. Jordan Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma Clin Rev Allergy 10 1992 39
92. Q. Yi A. Osterborg S. Bergenbrant Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies Blood 86 1995 3043